SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BEAM, BOL, KERA, LASE, LCAV, LVCI, LZRC, VISX, SNRS, STAA

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HerbVic who wrote (232)3/18/2000 2:17:00 PM
From: HerbVic   of 253
 
Here Polly! Get back on your perch Polly!

<<<excerpt>>>

Summit Wins FDA Panel Support for New Eye Laser Use (Update2)
By Brian Reid

(Closes shares.)

Rockville, Maryland, March 17 (Bloomberg) -- Summit
Technology Inc., the No. 2 eye laser maker, won the support of an
expert governmental panel for an expanded use of the eye laser
system Ladarvision.

The U.S. Food and Drug Administration advisory panel voted to
recommend that the agency allow the company to market the laser
made by its Autonomous Technologies unit to treat farsightedness.
It's already approved for nearsighted patients.

If the FDA follows the panel's recommendation, the laser will
have a range of approvals close to that of industry leader Visx
Inc.'s laser, which analysts said could give Summit a boost.
``It's important psychologically, in that the people who are
selling the machines would like to demonstrate that they have next-
generation technology,' said Kenneth Goldman, an analyst at
Lehman Brothers.

Summit markets another eye laser already approved for both
nearsightedness and farsightedness, though the Autonomous laser
would be the first approved for astigmatism in patients with
farsightedness.
``The sponsors did an excellent job in showing overall safety
and efficacy,' said Arthur Bradley, an associate professor at
Indiana University, one of two panel members who reviewed the
Summit data in detail.

Shares of Waltham, Massachusetts-based Summit, which have
fallen 8 percent this year, rose 1 1/16 to 10 3/4 in trading on
the Nasdaq Stock Market. Visx shares, which have lost more than 80
percent of their value this year, fell 7/16 to 15 15/16.

<<<snip>>>

The Ladarvision system -- an advanced laser that tracks the
movement of the eye to better place the pulses of laser energy --
could give summit an edge as it tries to boost its share in the
increasingly competitive eye laser market if it receives the
expanded indication.

quote.bloomberg.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext